ARCUTIS BIOTHERAPEUTICS, INC. (ARQT) - GUGGENHEIM 3RD ANNUAL HEALTHCARE INNOVATION CONFERENCE - ARCUTIS BIOTHERAPEUTICS INC

Financial Performance:

• Exited 2026 on track to achieve peak sales guidance of $2.3–$3.5 billion, having already surpassed $500 million in annual revenue.
• Achieved consistent cash flow positivity since Q4 2025, with net income positive in 3 of the last 4 quarters.
• Gross net pricing reached "steady state" early in the year with minimal price erosion expected in Q4 2026.
• Average patient utilization stands at 2–3 units annually for established indications (Psoriasis, AD).
• Transaction involving the sale of Zareve royalties to Royalty Pharma (previously held by AstraZeneca) has zero financial impact on Arcutis; the arrangement covers a 10-year window aligned with peak sales projections.

Guidance and Future Outlook:

• Raised 2026 guidance for the second time; outlook for 2027 is described as "bullish" with multiple growth catalysts.
• Key 2027 catalysts include: expansion of the pediatric and primary care sales teams, a new endorsement deal with Simone Biles, and the anticipated pediatric approval in late February.
• Management projects a market share shift in branded non-steroidals from the current ~3.5% to 15–20%, which would drive the product toward its $2.5–$3.5 billion peak sales target.
• Intends to remain cash flow positive throughout 2027, though occasional quarterly mismatches (e.g., bonus payments in March) may occur; major BD investments could temporarily alter this trajectory.

Business Segments and Product Lines:

• Zareve (crisaborole): Core product performing strongly in Psoriasis and Atopic Dermatitis (AD); gaining significant traction in Seborrheic Dermatitis.
• Pipeline Indications:
  • Vitiligo: Early Phase II data suggests efficacy in treating post-inflammatory hypopigmentation; mechanistic rationale includes anti-inflammatory and melanogenesis-promoting properties via PDE4 inhibition.
  • Hidradenitis Suppurativa (HS): Enrolling Phase III studies; focuses on using Zareve foam as monotherapy or adjunctive to biologics, leveraging anti-fibrotic and itch-pain alleviation mechanisms.
  • Moderate-to-Severe AD: Initiated Phase III study in late 2026 to capture the full severity spectrum ("cradle to cane").
• ARQ-234: Recent acquisition for atopic dermatitis; currently in Phase 1 multiple ascending dose with Proof of Concept (POC) data expected soon.
• Commercial Expansion: Sales force expanded in 2026; building out dedicated pediatric and primary care teams in early 2027.

Market and Competitive Landscape:

• Operating in a large market historically dominated by topical steroids but experiencing a structural shift away from steroids due to long-term safety concerns.
• Recent AAD guidelines now prefer non-steroidals over steroids for pediatric use; a multidisciplinary group has petitioned the FDA to update steroid labels.
• Competition from new topical non-steroidals (e.g., Upadacitinib, JAK inhibitors) is increasing, but Arcutis views its profile as best-in-class due to efficacy, safety, and rapid onset.
• Management notes that dermatologists historically prescribed 16x more topical steroids than non-steroidals in 2025, indicating a massive addressable market for switching.

Risks and Challenges:

• Clinical Risk: Success of upcoming Phase II (Vitiligo) and Phase III (HS, Moderate-Severe AD) trials is required to validate the expanded peak sales potential.
• Payer Dynamics: While multiple indications strengthen payer negotiation leverage, rebate structures differ between Psoriasis and AD, requiring tailored commercial strategies.
• Market Perception: Investor skepticism regarding whether any topical can sustain multi-billion dollar sales remains a hurdle, though management asserts recent data disproves this narrative.

Management Commentary and Tone:

• Tone is highly confident, "bullish," and aggressive regarding growth expectations and market displacement of steroids.
• CEO Frank Watanabe and CCO Rob Lesicki emphasize the "iceberg" analogy: 90% of the non-steroidal opportunity remains untapped.
• Management expresses strong pride in team execution, rapid development success, and the unique culture of the company.
• CFO Lata Virovan reinforced a disciplined capital allocation strategy focused on organic growth (sales/marketing) and selective, high-barrier BD deals.

Analyst Questions and Answers:

• Q: What surprised Rob Lesicki most about the company? A: The unique company culture (shared vision) and the rapid, successful completion of Phase 2/3 studies.
• Q: How will the Simone Biles partnership impact growth? A: Expected to raise awareness for Seborrheic Dermatitis and Eczema, specifically targeting new patient populations.
• Q: What are the utilization expectations for Vitiligo? A: Likely similar to other indications (2–3 units/year), driven by high visibility areas (face/hands), with potential upside.
• Q: Does the IP estate protect the product sufficiently? A: Yes; 28 issued patents (24 Orange Book listed), with protection extending to 2037 for cream and 2042 for foam.
• Q: What are the criteria for new BD deals? A: Focus on large markets with unmet need, biologically validated targets, and highly differentiated assets; deals are "nice to have" but not necessary given organic potential.

Other Key Points:

• Q4 is seasonally the strongest quarter; volume growth is expected to outpace price effects.
• The foam formulation of Zareve is a key differentiator for sensitive areas (groin, armpits) compared to creams, particularly for HS and pediatric use.
• The royalty sale to Royalty Pharma serves as an external validation of the company's peak sales potential by a major third-party financier.
• Management explicitly stated they have "proved people wrong," moving from predictions of a $400 million cap to a trajectory exceeding $500 million.